Effects of add-on mirtazapine on neurocognition in schizophrenia
Schizophrenia is a severe, psychiatric illness with neurocognitive deficits as its major component, and affects about 1% of the world population. Improving impaired neurocognitive function is one of the pivotal treatment goals in this patient population. In the treatment of schizophrenia, only a par...
Main Author: | |
---|---|
Other Authors: | , , , , , |
Format: | Doctoral or Postdoctoral Thesis |
Language: | English |
Published: |
Helsingin yliopisto
2013
|
Subjects: | |
Online Access: | http://hdl.handle.net/10138/42398 |
id |
ftunivhelsihelda:oai:helda.helsinki.fi:10138/42398 |
---|---|
record_format |
openpolar |
spelling |
ftunivhelsihelda:oai:helda.helsinki.fi:10138/42398 2023-08-20T04:07:42+02:00 Effects of add-on mirtazapine on neurocognition in schizophrenia Stenberg, Jan-Henry Hintikka, Jukka University of Helsinki, Faculty of Medicine, Institute of Clinical Medicine, Department of Psychiatry Helsingin yliopisto, lääketieteellinen tiedekunta, kliininen laitos Helsingfors universitet, medicinska fakulteten, institutionen för klinisk medicin Joffe, Grigori Tiihonen, Jari 2013-12-30T08:37:45Z application/pdf http://hdl.handle.net/10138/42398 eng eng Helsingin yliopisto Helsingfors universitet University of Helsinki URN:ISBN:978-952-10-9710-2 Unigrafia: 2014 http://hdl.handle.net/10138/42398 URN:ISBN:978-952-10-9711-9 Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty. This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited. Publikationen är skyddad av upphovsrätten. Den får läsas och skrivas ut för personligt bruk. Användning i kommersiellt syfte är förbjuden. lääketiede Text Doctoral dissertation (article-based) Artikkeliväitöskirja Artikelavhandling doctoralThesis 2013 ftunivhelsihelda 2023-07-28T06:17:49Z Schizophrenia is a severe, psychiatric illness with neurocognitive deficits as its major component, and affects about 1% of the world population. Improving impaired neurocognitive function is one of the pivotal treatment goals in this patient population. In the treatment of schizophrenia, only a partial treatment response is typically achieved with dopamine antagonists; i.e., antipsychotics . The antidepressant mirtazapine has a unique mechanism of action with, in theory, an ability to enhance neurocognition and provide added value to antipsychotic treatment. This study explored whether or not adjunctive mirtazapine has the potential to improve neurocognitive performance and alleviate clinical symptoms in patients with schizophrenia who demonstrated a suboptimal treatment response to first-generation antipsychotics (FGAs). This study was a neurocognitive arm of a single-center, randomized, add-on, double-blinded, placebo-controlled study, which was carried out in the Karelian Republic, Petrozavodsk, Russia. Patients with schizophrenia or a depressive type schizoaffective disorder, according to the Diagnostic and Statistical Manual of Mental and Behavioral Disorders 4th edition (DSM-IV) criteria, who received stable doses of FGA with inadequate treatment response were enrolled into the trial. Twenty patients were assigned to mirtazapine and 21 to placebo. After a one-week single-blind placebo run-in period, the participants were randomized to receive either 30 mg of mirtazapine or the placebo four times a day (QID) in a double-blind fashion for 6 weeks. Subsequently, those who were eligible to continue entered the following 6-week open-label phase, where they were treated with mirtazapine 30 mg QID. At study weeks 0, 6, and 12, a senior psychologist performed neuropsychological examinations to evaluate neurocognitive functioning. Verbal and visual memory, visuo-spatial and executive functions, verbal fluency and both general mental and psychomotor speeds were assessed by commonly used, validated ... Doctoral or Postdoctoral Thesis karelia* karelian Helsingfors Universitet: HELDA – Helsingin yliopiston digitaalinen arkisto |
institution |
Open Polar |
collection |
Helsingfors Universitet: HELDA – Helsingin yliopiston digitaalinen arkisto |
op_collection_id |
ftunivhelsihelda |
language |
English |
topic |
lääketiede |
spellingShingle |
lääketiede Stenberg, Jan-Henry Effects of add-on mirtazapine on neurocognition in schizophrenia |
topic_facet |
lääketiede |
description |
Schizophrenia is a severe, psychiatric illness with neurocognitive deficits as its major component, and affects about 1% of the world population. Improving impaired neurocognitive function is one of the pivotal treatment goals in this patient population. In the treatment of schizophrenia, only a partial treatment response is typically achieved with dopamine antagonists; i.e., antipsychotics . The antidepressant mirtazapine has a unique mechanism of action with, in theory, an ability to enhance neurocognition and provide added value to antipsychotic treatment. This study explored whether or not adjunctive mirtazapine has the potential to improve neurocognitive performance and alleviate clinical symptoms in patients with schizophrenia who demonstrated a suboptimal treatment response to first-generation antipsychotics (FGAs). This study was a neurocognitive arm of a single-center, randomized, add-on, double-blinded, placebo-controlled study, which was carried out in the Karelian Republic, Petrozavodsk, Russia. Patients with schizophrenia or a depressive type schizoaffective disorder, according to the Diagnostic and Statistical Manual of Mental and Behavioral Disorders 4th edition (DSM-IV) criteria, who received stable doses of FGA with inadequate treatment response were enrolled into the trial. Twenty patients were assigned to mirtazapine and 21 to placebo. After a one-week single-blind placebo run-in period, the participants were randomized to receive either 30 mg of mirtazapine or the placebo four times a day (QID) in a double-blind fashion for 6 weeks. Subsequently, those who were eligible to continue entered the following 6-week open-label phase, where they were treated with mirtazapine 30 mg QID. At study weeks 0, 6, and 12, a senior psychologist performed neuropsychological examinations to evaluate neurocognitive functioning. Verbal and visual memory, visuo-spatial and executive functions, verbal fluency and both general mental and psychomotor speeds were assessed by commonly used, validated ... |
author2 |
Hintikka, Jukka University of Helsinki, Faculty of Medicine, Institute of Clinical Medicine, Department of Psychiatry Helsingin yliopisto, lääketieteellinen tiedekunta, kliininen laitos Helsingfors universitet, medicinska fakulteten, institutionen för klinisk medicin Joffe, Grigori Tiihonen, Jari |
format |
Doctoral or Postdoctoral Thesis |
author |
Stenberg, Jan-Henry |
author_facet |
Stenberg, Jan-Henry |
author_sort |
Stenberg, Jan-Henry |
title |
Effects of add-on mirtazapine on neurocognition in schizophrenia |
title_short |
Effects of add-on mirtazapine on neurocognition in schizophrenia |
title_full |
Effects of add-on mirtazapine on neurocognition in schizophrenia |
title_fullStr |
Effects of add-on mirtazapine on neurocognition in schizophrenia |
title_full_unstemmed |
Effects of add-on mirtazapine on neurocognition in schizophrenia |
title_sort |
effects of add-on mirtazapine on neurocognition in schizophrenia |
publisher |
Helsingin yliopisto |
publishDate |
2013 |
url |
http://hdl.handle.net/10138/42398 |
genre |
karelia* karelian |
genre_facet |
karelia* karelian |
op_relation |
URN:ISBN:978-952-10-9710-2 Unigrafia: 2014 http://hdl.handle.net/10138/42398 URN:ISBN:978-952-10-9711-9 |
op_rights |
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty. This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited. Publikationen är skyddad av upphovsrätten. Den får läsas och skrivas ut för personligt bruk. Användning i kommersiellt syfte är förbjuden. |
_version_ |
1774719533511081984 |